- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01616927
Study of Lanreotide to Treat Polycystic Kidney Disease (DIPAK1)
The DIPAK 1 Study: A Randomised, Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation in both kidneys, in most patients leading to end stage renal disease. It is the most common hereditary renal disease with a prevalence of approximately 1 in 1,000 persons. The majority of patients also have progressive cyst formation in the liver, leading to pain, gastrointestinal discomfort and sometimes the need for liver transplantation. At present there is no proven therapeutic intervention to slow the rate of disease progression in human ADPKD. The development of renoprotective treatments that are well tolerated, is therefore of major importance.
In this respect, somatostatin analogues are promising for especially polycystic liver disease, but also for the renal phenotype. However, the studies that have been performed thus far with these agents, were underpowered and of too short duration to reach a definitive conclusion on the potential reno- and hepatoprotective efficacy of somatostatin analogues. Therefore, the present study is designed as a randomised clinical trial with sufficient duration of follow-up to investigate whether the somatostatin analogue Lanreotide slows progression of polycystic kidney and liver disease in ADPKD-patients.
To this end, 300 ADPKD patients, aged 18-60years, with an eGFR 30-60 ml/min/1.73 m2) will be randomized 1:1 to standard care or monthly subcutaneous lanreotide injections on top off standard care. These 300 subjects will go through 15 study visits in 3 years and 1 follow up visit. During these visits, questionnaires will be filled in, physical examinations will be performed, blood will be drawn and urine collected. After study completion, rate of renal function decline in lanreotide treated subjects will be compared to that of subject who received standard care.
Study Overview
Status
Intervention / Treatment
Detailed Description
Aims:
First, to determine whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measured by change in rate of renal function decline and change in renal volume growth.
Second, to determine whether Lanreotide modifies progression of the liver phenotype in the subset of ADPKD patients with moderate to severe polycystic liver disease as measured by change in liver volume.
Methods:
Investigator driven, randomized, multi-center, controlled clinical trial.
Study population:
300 subjects, diagnosed with ADPKD, based on the revised Ravine criteria, with advanced disease and high likelihood of rapid disease progression (eGFR between 30 and 60 ml/min/1.73 m2 and age between 18 and 60 years).
Intervention:
Patients will be randomized (1:1) into two groups. One group will receive a dose of Lanreotide 120 mg sc every 28 days for 30 months. The dose of Lanreotide will be eGFR (BSA unadjusted) dependent. Subjects that reach an eGFR <30ml/min during the study will receive Lanreotide 90 mg sc every 28 days. Down-titration will also occur in case of dose related side effects. The other group of patients will receive standard care.
Main study endpoint:
Change in renal function in Lanreotide versus not treated patients, as assessed as slope through serial eGFR measurements over time during the treatment phase of the trial, with the value obtained at month 3 as first eGFR value for slope analysis.
Main secondary outcome variables:
- to determine whether Lanreotide modifies ADPKD progression as measured by change in renal volume in the overall study population,
- to determine whether Lanreotide modifies ADPKD progression as measured by change in liver volume in the subset of ADPKD patients with moderate to severe polycystic liver disease
- to determine whether Lanreotide changes the quality of life
- to determine whether Lanreotide is well tolerated
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Groningen, Netherlands
- University Medical Center Groningen
-
Leiden, Netherlands
- Leiden University Medical Center
-
Nijmegen, Netherlands
- Radboud university medical center
-
Rotterdam, Netherlands
- Erasmus Medisch Centrum
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of ADPKD, based upon the modified Ravine criteria
- Age between 18 and 60 years.
- eGFR (MDRD) between 30 and 60 ml/min/1.73 m2.
- Providing informed consent.
Exclusion Criteria:
- Patients who, in the opinion of the study investigator may present a safety risk.
- Patients who are unlikely to adequately comply with the trial's procedures [due for instance to medical conditions likely to require an extended interruption or discontinuation, history of substance abuse or noncompliance).
- a. Patients taking medications or having concomitant illnesses likely to confound endpoint assessments (e.g. nephrotoxic medications such as chronic NSAID, cyclosporine, lithium immunosuppressant use) b. Patients having concomitant illnesses likely to confound endpoint assessments (e.g. diabetes mellitus for which medication is needed and patients with proteinuria > 1 g /24hr).
- Patients who underwent surgical or drainage interventions for cystic kidney disease the year before study-entry or are likely candidates for these procedures within 2 years of start of the study.
- Patients taking other experimental (i.e.,non approved by FDA/EMA or indication of ADPKD) therapies.
- Patients having used Lanreotide (or another somatostatin analogue) in the 3 months before study start.
- Patients with known intolerance for Lanreotide (or another somatostatin analogue).
- Unwillingness to comply with reproductive precautions. Women who are capable of becoming pregnant must be willing to comply with approved birth control from two-weeks prior to, and for 60 days after taking investigational product.
- Women, who are pregnant or breastfeeding.
- Patients, who suffer from cardiac arrhythmias, that are thought to be dangerous in combination with lanreotide administration.
- Patients, who ever suffered from symptomatic gallstones and did not undergo cholecystectomy.
- Patients, who have a medical history of pancreatitis.
- Patients, who have a medical history of infected liver cysts.
In addition:
- Patients, who underwent liver cyst drainage or surgery in the year before, can enter the study, but will not be assessed for change in liver volume.
- Patients having contraindications to, or interference with MRI assessments, as dictated by local regulation, will not be allowed to undergo MR imaging. However, these patients can enter the study, but will not be assessed for change in kidney and/or liver volume.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: standard care
Subjects in this arm will receive standard care
|
|
Experimental: Lanreotide
|
Lanreotide will be administered once every 4 weeks as a subcutaneous injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in renal function
Time Frame: serial eGFR measurements from month 3 until end of treatment visit (month 30)
|
Change in renal function in Lanreotide versus not treated patients, as assessed as slope through all eGFR measurements taken at study visits during the treatment phase of the trial (n=10), with the value obtained at month 3 as first eGFR value for slope analysis.
|
serial eGFR measurements from month 3 until end of treatment visit (month 30)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in renal volume
Time Frame: baseline and 3 months after end of treatment (follow-up; month 33)
|
to determine whether Lanreotide modifies ADPKD progression as measured by change in renal volume in the overall study population.
Renal volume is measured at baseline, after 30 months of treatment and 3 months afterwards (follow-up visit).
|
baseline and 3 months after end of treatment (follow-up; month 33)
|
change in liver volume
Time Frame: Baseline and end of treatment (month 30)
|
to determine whether Lanreotide modifies ADPKD progression as measured by change in liver volume in the subset of ADPKD patients with moderate to severe polycystic liver disease, defined as a liver volume of >2000 ml.
Liver volume is measured at baseline, at month 30 and 3 months afterwards (follow-up visit))
|
Baseline and end of treatment (month 30)
|
change in quality of life
Time Frame: baseline-end of treatment (month 30)
|
to determine whether Lanreotide changes the quality of life (using specific questionnaires).
These questionnaires will be filled in at baseline, after 3 months of treatment, after 1 year, after 2 years, at end of treatment (30 months) and at follow-up (3 months after end of treatment)
|
baseline-end of treatment (month 30)
|
tolerance
Time Frame: baseline-end of treatment(month 30)
|
to determine whether lanreotide is safe and well tolerated.
This is assessed by investigating (severe)adverse events, vital signs, performing physical examination and clinical laboratory tests.
|
baseline-end of treatment(month 30)
|
change in renal function
Time Frame: baseline and 3 months after end of treatment (follow-up; month 33)
|
change in renal function in Lanreotide versus not treated patients, as assessed as change in eGFR from baseline versus eGFR obtained 3 months after cessation of treatment.
|
baseline and 3 months after end of treatment (follow-up; month 33)
|
Incidence of worsening renal function
Time Frame: from baseline
|
incidence of worsening renal function defined as a 30% decrease in eGFR and/or need for renal replacement therapy computed from pre-treatment eGFR
|
from baseline
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ron Gansevoort, MD, PhD, University Medical Centre
Publications and helpful links
General Publications
- Meijer E, Drenth JP, d'Agnolo H, Casteleijn NF, de Fijter JW, Gevers TJ, Kappert P, Peters DJ, Salih M, Soonawala D, Spithoven EM, Torres VE, Visser FW, Wetzels JF, Zietse R, Gansevoort RT; DIPAK Consortium. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2014 Mar;63(3):446-55. doi: 10.1053/j.ajkd.2013.10.011. Epub 2013 Dec 15.
- Lantinga MA, D'Agnolo HM, Casteleijn NF, de Fijter JW, Meijer E, Messchendorp AL, Peters DJ, Salih M, Spithoven EM, Soonawala D, Visser FW, Wetzels JF, Zietse R, Drenth JP, Gansevoort RT; DIPAK Consortium. Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study. Drug Saf. 2017 Feb;40(2):153-167. doi: 10.1007/s40264-016-0486-x.
- Aapkes SE, de Haas RJ, Bernts LHP, Blijdorp CJ, Dekker SEI, van Gastel MDA, Meijer E, Veldman A, Drenth JPH, Gansevoort RT; DIPAK consortium. Incident Gallstones During Somatostatin Analog Treatment are Associated with Acute Biliary Complications Especially After Discontinuation. Drugs R D. 2021 Jun;21(2):179-188. doi: 10.1007/s40268-021-00342-7. Epub 2021 Mar 29.
- van Aerts RMM, Kievit W, D'Agnolo HMA, Blijdorp CJ, Casteleijn NF, Dekker SEI, de Fijter JW, van Gastel M, Gevers TJ, van de Laarschot LFM, Lantinga MA, Losekoot M, Meijer E, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, Drenth JPH; DIPAK-1 Investigators. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease. Gastroenterology. 2019 Aug;157(2):481-491.e7. doi: 10.1053/j.gastro.2019.04.018. Epub 2019 Apr 22.
- Meijer E, Visser FW, van Aerts RMM, Blijdorp CJ, Casteleijn NF, D'Agnolo HMA, Dekker SEI, Drenth JPH, de Fijter JW, van Gastel MDA, Gevers TJ, Lantinga MA, Losekoot M, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Wetzels JF, Zietse R, Gansevoort RT; DIPAK-1 Investigators. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial. JAMA. 2018 Nov 20;320(19):2010-2019. doi: 10.1001/jama.2018.15870.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urologic Diseases
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Abnormalities, Multiple
- Kidney Diseases, Cystic
- Ciliopathies
- Kidney Diseases
- Polycystic Kidney Diseases
- Polycystic Kidney, Autosomal Dominant
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Lanreotide
- Somatostatin
Other Study ID Numbers
- DIPAK1
- 2011-005017-37 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autosomal Dominant Polycystic Kidney Disease (ADPKD)
-
University of North Carolina, Chapel HillNational Institute of General Medical Sciences (NIGMS)CompletedRenal Disease | Autosomal Dominant Polycystic Kidney Disease | ADPKDUnited States
-
Kadmon Corporation, LLCTerminatedAutosomal Dominant Polycystic Kidney Disease (ADPKD)United States
-
Assistance Publique - Hôpitaux de ParisIPSEN pharmaceutical company, Boulogne-Billancourt, FranceCompletedAutosomal Dominant Polycystic Kidney Disease (ADPKDFrance
-
Mario Negri Institute for Pharmacological ResearchCompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD)Italy
-
Palladio BiosciencesCentessa Pharmaceuticals plcTerminatedADPKD | Polycystic Kidney Disease, AdultUnited States
-
Children's National Research InstituteRecruiting
-
Tufts Medical CenterCompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD)United States
-
Vertex Pharmaceuticals IncorporatedNot yet recruitingAutosomal Dominant Polycystic Kidney Disease (ADPKD)
-
University of CologneRecruitingADPKD (Autosomal Dominant Polycystic Kidney Disease)Germany
-
University of ZurichCompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD)Switzerland
Clinical Trials on Lanreotide
-
University Hospital, GhentCompleted
-
IpsenCompleted
-
IpsenCompletedCarcinoma | Peritoneal Neoplasms | Intestinal ObstructionFrance, Netherlands, Belgium
-
Radboud University Medical CenterIpsenUnknownLiver Diseases | Hepatomegaly | Polycystic Liver Disease | Polycystic Kidney | Autosomal DominantNetherlands, Belgium
-
IpsenCompleted
-
Asan Medical CenterSamsung Medical Center; Seoul St. Mary's Hospital; Seoul National University... and other collaboratorsRecruitingNeuroendocrine TumorsKorea, Republic of
-
Federation Francophone de Cancerologie DigestiveTerminatedMetastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine TumoursFrance, Belgium, Germany, United Kingdom
-
University Hospital, GhentIpsenCompleted
-
IpsenCompletedGastroenteropancreatic Neuroendocrine TumorChina
-
IpsenCompletedAcromegalyFrance, Switzerland